Journal article · 2025 · Open access
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial
JAMA, 335(9), 763 · Published 12 December 2025 · DOI 10.1001/jama.2025.24784
In brief
“Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial” is a 2025 journal article by Laura J. Esserman and 38 co-authors, published in JAMA. OpenAlex counts 85 citations as of 17 November 2026, which puts it in the top 5% of works published in 2025 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 85
- Most cited in
- 2026 (82)
- Field-weighted impact
- 33.16
- References
- 48
- Authors
- 39
Abstract
Importance: Individual breast cancer risk can guide screening initiation, frequency, use of supplemental imaging, and preventive measures to improve breast cancer screening by shifting resources from low-risk women to high-risk women. Objective: To determine whether risk-based breast cancer screening is a feasible alternative to annual mammography. Design, Setting, and Participants: Parallel-group, pragmatic, multicenter randomized clinical trial comparing risk-based (n = 14 212) with annual (n = 14 160) breast cancer screening. Women aged 40 to 74 years without prior diagnoses of breast cancer or ductal carcinoma in situ, or prophylactic bilateral mastectomy, were recruited from all 50 US states from September 2016 to February 2023, with follow-up through September 5, 2025 (median follow-up, 5.1 years). Statistical analysis was conducted between July and November 2025. All study procedures were conducted via an online platform. Women who declined randomization were enrolled in an observational cohort. Interventions: Risk assessment included sequencing of 9 susceptibility genes, polygenic risk score, and the Breast Cancer Surveillance Consortium version 2 model. The risk-based group received 1 of 4 recommendations: (1) highest risk (≥6% 5-year risk, high-penetrance pathogenic variant): alternating mammography and magnetic resonance imaging (MRI) every 6 months and counseling; (2) elevated risk (top 2.5 risk percentile by age): annual mammography and risk-reduction counseling; (3) average risk: biennial mammography; and (4) low risk (aged 40-49 years and <1.3% 5-year risk): no screening until risk is 1.3% or greater or age 50 years. Main Outcomes and Measures: The coprimary outcomes included noninferiority for stage ≥IIB cancers and superiority in reducing biopsy rates. Secondary outcomes included identification of stage ≥IIA cancers, mammogram rates, uptake of prevention strategies in higher risk cohorts, preference for screening group in the observational cohort, ductal carcinoma in situ, MRI, and stage-specific cancer rates. Results: A total of 28 372 women were randomized. The mean (SD) age was 54 (9.6) years and the majority were non-Hispanic White (77%). The rate of stage ≥IIB cancers was noninferior in the risk-based compared with the annual group (risk-based: 30.0 [95% CI, 16.3-43.8] vs annual: 48.0 [95% CI, 30.1-65.5] per 100 000 person-years; rate difference, -18.0 per 100 000 person-years [95% CI, -40.2 to 4.1]). The rate of breast biopsies was not lower in the risk-based group (rate difference, 98.7 per 100 000 person-years [95% CI, -17.9 to 215.3]) despite fewer mammograms (rate difference, -3835.9 [95% CI, -4516.8 to -3154.9]). The cumulative incidence of cancer, biopsy, mammogram, and MRI increased as risk category increased. In the observational cohort, 89% of participants (15 980/18 031) chose risk based. Conclusions: Risk-based…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Esserman, L. J., Fiscalini, A. S., Naeim, A., Veer, L. J. V., Kaster, A., Scheuner, M. T., LaCroix, A. Z., Borowsky, A. D., Anton‐Culver, H., Olopade, O. I., Esserman, J., Lancaster, R. B., Madlensky, L., Blanco, A. M., Ross, K. S., Goodman, D., Tong, B., Hogarth, M. A., Heditsian, D. M., . . . Eklund, M. (2025). Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA, 335(9), 763. https://doi.org/10.1001/jama.2025.24784
MLA 9
Esserman, Laura J., et al. “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.” JAMA, vol. 335, no. 9, 2025, p. 763. https://doi.org/10.1001/jama.2025.24784.
Chicago
Esserman, Laura J., Allison Stover Fiscalini, Arash Naeim, Laura J. van’t Veer, Andrea Kaster, Maren Theresa Scheuner, Andrea Z. LaCroix, et al. 2025. “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.” JAMA 335 (9): 763. https://doi.org/10.1001/jama.2025.24784.
Harvard
Esserman, L. J. et al. (2025) ‘Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial’, JAMA, 335(9), p. 763. doi:10.1001/jama.2025.24784.
IEEE
L. J. Esserman et al., “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial,” JAMA, vol. 335, no. 9, p. 763, 2025, doi: 10.1001/jama.2025.24784.
BibTeX
@article{esserman2025risk,
title = {{Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial}},
author = {Esserman, Laura J. and Fiscalini, Allison Stover and Naeim, Arash and Veer, Laura J. van’t and Kaster, Andrea and Scheuner, Maren Theresa and LaCroix, Andrea Z. and Borowsky, Alexander D. and Anton‐Culver, Hoda and Olopade, Olufunmilayo Ibironke and Esserman, James and Lancaster, Rachael B. and Madlensky, Lisa and Blanco, Amie M and Ross, Katherine S. and Goodman, Deborah and Tong, Barry and Hogarth, Michael A. and Heditsian, Diane Marie and Brain, Susie and Lee, Vivian and Blum, Kelly and Kim, Mi‐Ok and Sabacan, Leah P. and Fergus, Kirkpatrick B. and Yau, Christina S. F. and Park, Hannah L. and Parker, Barbara A. and Kaplan, Celia Patricia and Rhoads, Kim Felder and others},
journal = {JAMA},
year = {2025},
volume = {335},
number = {9},
pages = {763},
doi = {10.1001/jama.2025.24784},
url = {https://doi.org/10.1001/jama.2025.24784}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Digital Radiography and Breast Imaging
- annual mammography
- breast cancer risk prediction
- polygenic risk score
- BRCA mutations
- magnetic resonance imaging screening
- breast cancer stage at diagnosis
- risk reduction counseling
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Esserman, L. J., Fiscalini, A. S., Naeim, A., Veer, L. J. V., Kaster, A., Scheuner, M. T., LaCroix, A. Z., Borowsky, A. D., Anton‐Culver, H., Olopade, O. I., Esserman, J., Lancaster, R. B., Madlensky, L., Blanco, A. M., Ross, K. S., Goodman, D., Tong, B., Hogarth, M. A., Heditsian, D. M., . . . Eklund, M. (2025). Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA, 335(9), 763. https://doi.org/10.1001/jama.2025.24784
How many times has this paper been cited?
85 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Laura J. Esserman, Allison Stover Fiscalini, Arash Naeim, Laura J. van’t Veer, Andrea Kaster, Maren Theresa Scheuner, Andrea Z. LaCroix, Alexander D. Borowsky, Hoda Anton‐Culver, Olufunmilayo Ibironke Olopade, James Esserman, Rachael B. Lancaster and 27 more.
What is the DOI of this paper?
10.1001/jama.2025.24784, permanently at https://doi.org/10.1001/jama.2025.24784. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.